

EVOLUTION T2D

REFERENCE LIST

MODULE 1: Perspectives on the Evolution of T2D Management

A Brief History of Game Changers and Current Goals for Holistic Management

- Anker SD, et al. N Engl J Med 2021;385:1451-61
Cheng AYY, et al. Can J Diabetes. 2021;45:580-87
Dahl D, et al. JAMA. 2022; 327(6):534-45
Davies M, et al. Lancet. 2021;397(10278):971-984
Davies MJ, et al. Diabetologia. 2022;65(12):1925-66
Del Prato S, et al. Lancet. 2021; 398(10313):1811-24
Frías JP, et al. N Engl J Med. 2021; 385(6):503-15
Gerstein HC, et al. Lancet. 2019; 394(10193):121-30
Heerspink HJL, et al. N Engl J Med. 2020;383(15):1436-46
Lipscombe L, et al. Can J Diabetes. 2020; 44:575-91
Ludvik B, et al. Lancet. 2021; 398(10300):583-98
Mackay D, et al. Can J Diabetes. 2022;46:753-761
Marso S, et al. N Engl J Med. 2016; 375(4):311-22
Marso S, et al. N Engl J Med. 2016; 375:1834-44
McMurray JJ, et al. N Engl J Med. 2019;381(21):1995-2008
Meltzer S, et al. CMAJ 1998. 159(8 Suppl):S1-29
Nature Reviews Endocrinology. Milestones Diabetes. 2021;S1-S26.
Neal B, et al. N Engl J Med. 2017;377(7):644-57
Packer M, et al. N Engl J Med. 2020;383(15):1413-24
Perkovic V, et al. N Engl J Med. 2019;380(24):2295-306
Rosenstock J, et al. Lancet. 2021; 398(10295):143-55
Rosenstock J et al. Presented at American Diabetes Association – 83rd Annual Scientific Sessions; 2023. Poster 750-P
Solomon SD, et al. N Engl J Med. 2022;387(12):1089-98
The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-27
Wiviott SD, et al. N Engl J Med. 2019;380(4):347-57
Zinman B, et al. N Engl J Med. 2015;373(22):2117-28

EVOLUTION T2D

MODULE 2: The Ongoing Evolution of Incretin Therapy for T2D

My Game Changer: The unprecedented A1C-lowering and body-weight effects of the latest incretin-based therapy

Clinicaltrials.gov. NCT04255433

Dahl D, et al. *JAMA*. 2022; 327(6):534-45

Del Prato S, et al. *Lancet*. 2021; 398(10313):1811-24

Drucker DJ, et al. *Diabetologia*. 2023 Mar 28. [Epub ahead of print]

Frías JP, et al. *N Engl J Med*. 2021; 385(6):503-15

Gasbjerg LS, et al. *Diabetes Obes Metab*. 2021; 23(1):68-74

Hammoud R, et al. *Nat Rev Endocrinol*. 2023;19(4):201-16

Holst JJ, et al. *Endocrinology*. 2021;162(7):bqab065

Lipscombe L, et al. *Can J Diabetes*. 2020; 44:575-91

Ludvik B, et al. *Lancet*. 2021; 398(10300):583-98

Rosenstock J, et al. *Lancet*. 2021; 398(10295):143-55

Rosenstock J et al. Presented at American Diabetes Association – 83rd Annual Scientific Sessions; 2023. Poster 750-P

Skow MA, et al. *Diabetes Obes Metab*. 2016; 18(9):847-54

MODULE 3: The Evolution of Glycemic Targets in T2D

My Game Changer: The realistic possibility of lower A1C goals (e.g., <5.7%) for many patients
A1C, glycated hemoglobin

Dahl D, et al. *JAMA*. 2022; 327(6):534-45

Del Prato S, et al. *Lancet*. 2021; 398(10313):1811-24

Frías JP, et al. *N Engl J Med*. 2021; 385(6):503-15

Ikramuddin S, et al. *JAMA*. 2018; 319(3):266-278

Ludvik B, et al. *Lancet*. 2021; 398(10300):583-98

Mackay D, et al. *Can J Diabetes*. 2022;46:753-761

Rosenstock J, et al. *Lancet*. 2021; 398(10295):143-55

Rosenstock J et al. Presented at American Diabetes Association – 83rd Annual Scientific Sessions; 2023. Poster 750-P



EVOLUTION T2D

MODULE 4: The Evolution of T2D Management: Conclusions Reflections on Key Recent Game Changers in T2D Management

American Diabetes Association. *Diabetes Care*. 2021;44(Suppl 1):S73-S84
Cheng AYY, et al. *Can J Diabetes*. 2021;45:580-87
Imran SL, et al. *Can J Diabetes*. 2018;42(suppl.):S42-S46

MODULE 5: Incorporating The Latest Game Changers into Everyday Practice Where Does the Newest Class of Antihyperglycemic Therapy Fit?

Case 1 Support Slides

ClinicalTrials.gov Identifier: NCT04255433
Lipscombe L, et al. *Can J Diabetes*. 2020; 44:575-91
McGuire DK, et al. *JAMA Cardiol*. 2021; 6(2):148-58

Case 2 Support Slides

Del Prato S, et al. *Lancet*. 2021; 398(10313):1811-24
Frías JP, et al. *N Engl J Med*. 2021;385(6):503-15
Lipscombe L, et al. *Can J Diabetes*. 2020; 44:575-91
Ludvik B, et al. *Lancet*. 2021; 398(10300):583-98

Case 3 Support Slides

Lipscombe L, et al. *Can J Diabetes*. 2020; 44:575-91
Rosenstock J, et al. *Diabetes Care*. 2020;43(10):2509-2518
Rosenstock J et al. Presented at American Diabetes Association – 83rd Annual Scientific Sessions; 2023. Poster 750-P